B002 / Shanghai Pharma  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
B002 / Shanghai Pharma
B002-101, NCT04382352: B002 in Patients With HER2-positive Breast Cancer

Completed
1
23
RoW
Humanized Anti-HER2 Monoclonal Antibody Compound for Injection .R&D code: B002., Biological Products, Humanized Anti-HER2 Monoclonal Antibody Compound for Injection
Shanghai Pharmaceuticals Holding Co., Ltd
Recurrent Breast Cancer, Metastatic Breast Cancer
04/22
04/22

Download Options